Genomic Evolution of Patients with Myelodysplastic Syndrome after Hypomethylating Agent Failure
Kelly S. Chien, Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Yue Wei(The University of Texas MD Anderson Cancer Center), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Guillermo Montalban‐Bravo(The University of Texas MD Anderson Cancer Center), Sherry Pierce(The University of Texas MD Anderson Cancer Center), Hui Yang(The University of Texas MD Anderson Cancer Center), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Simona Colla(The University of Texas MD Anderson Cancer Center), Rashmi Kanagal‐Shamanna(The University of Texas MD Anderson Cancer Center), Yesid Alvarado(The University of Texas MD Anderson Cancer Center), Irene Gañán‐Gómez(The University of Texas MD Anderson Cancer Center), Danielle Hammond(The University of Texas MD Anderson Cancer Center), Kunhwa Kim(The University of Texas MD Anderson Cancer Center), Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Nicholas J. Short(The University of Texas MD Anderson Cancer Center), Ziyi Li(The University of Texas MD Anderson Cancer Center), Xiao Qin Dong(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Hagop Kantarjian(The University of Texas MD Anderson Cancer Center), Faustine Ong(The University of Texas MD Anderson Cancer Center)
Cited by 0
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
|New England Journal of Medicine|2002|2k
Acute myeloid leukemia: current progress and future directions
|Blood Cancer Journal|2021|750